Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales
This article was originally published in The Pink Sheet Daily
Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.
You may also be interested in...
Company, however, reaffirms EPS guidance for the year.
Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.
Agency requires more time to analyze hypersensitivity study, firm says.